Neos Therapeutics Inc. (NEOS) Trading Up 6.5%
Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) were up 6.5% during mid-day trading on Wednesday . The stock traded as high as $9.16 and last traded at $9.16, with a volume of 57,969 shares traded. The stock had previously closed at $8.60.
Several analysts recently issued reports on NEOS shares. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Royal Bank Of Canada cut their target price on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. Finally, BMO Capital Markets restated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, July 19th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Neos Therapeutics has a consensus rating of “Buy” and an average target price of $21.75.
The firm’s market cap is $140.39 million. The company has a 50-day moving average price of $9.24 and a 200 day moving average price of $9.78.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.08. Equities research analysts forecast that Neos Therapeutics Inc. will post ($4.88) EPS for the current year.
In other news, Director Gregory J. Robitaille bought 7,442 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were acquired at an average price of $7.55 per share, with a total value of $56,187.10. Following the acquisition, the director now owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Juergen Martens bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the acquisition, the insider now directly owns 10,000 shares in the company, valued at approximately $99,000. The disclosure for this purchase can be found here.
An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP boosted its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).